Pedro Farinha

List of Publications by Citations

104 papers	8,967 citations	36 h-index	94 g-index
110 ext. papers	10,355 ext. citations	6.2 avg, IF	5.13 L-index

#	Paper	IF	Citations
104	Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. *Blood*, **2004**, 103, 275-82	2.2	2955
103	Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. *New England Journal of Medicine*, **2010**, 362, 875-85	59.2	961
102	MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. *Blood*, **2009**, 114, 3533-7	2.2	484
101	MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. *Nature*, **2011**, 471, 377-81	50.4	467
100	Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). *Blood*, **2005**, 106, 2169-74	2.2	386
99	Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma. *Blood*, **2008**, 111, 3701-13	2.2	287
98	Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies. *Journal of Clinical Oncology*, **2015**, 33, 2848-56	2.2	236
97	The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL. *Blood*, **2009**, 113, 5536-48	2.2	179
96	Gene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphoma. *Journal of Clinical Oncology*, **2013**, 31, 692-700	2.2	145
95	The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation. *Blood*, **2010**, 115, 289-95	2.2	145
94	LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab. *Journal of Clinical Oncology*, **2008**, 26, 447-54	2.2	143
93	Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma. *Journal of Clinical Oncology*, **2019**, 37, 190-201	2.2	137
92	Molecular pathogenesis of mucosa-associated lymphoid tissue lymphoma. *Journal of Clinical Oncology*, **2005**, 23, 6370-8	2.2	137
91	Helicobacter pylori and MALT lymphoma. *Gastroenterology*, **2005**, 128, 1579-605	13.3	131
90	Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma. *Clinical Cancer Research*, **2005**, 11, 1065-72	12.9	127
89	Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition. *Cancer Discovery*, **2019**, 9, 546-563	24.4	123
88	Genome-wide copy number analysis of Hodgkin Reed-Sternberg cells identifies recurrent imbalances with correlations to treatment outcome. *Blood*, **2010**, 116, 418-27	2.2	123

87	Prognostic factors in follicular lymphoma. *Journal of Clinical Oncology*, **2010**, 28, 2902-13	2.2	117
86	Histological Transformation and Progression in Follicular Lymphoma: A Clonal Evolution Study. *PLoS Medicine*, **2016**, 13, e1002197	11.6	110
85	High-grade B-cell lymphoma with and and/or rearrangements with diffuse large B-cell lymphoma morphology. *Blood*, **2018**, 131, 2060-2064	2.2	107
84	Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL. *Blood*, **2016**, 127, 2182-8	2.2	105
83	Gene expression profiling of microdissected Hodgkin Reed-Sternberg cells correlates with treatment outcome in classical Hodgkin lymphoma. *Blood*, **2012**, 120, 3530-40	2.2	100
82	Genomic Alterations in CIITA Are Frequent in Primary Mediastinal Large B Cell Lymphoma and Are Associated with Diminished MHC Class II Expression. *Cell Reports*, **2015**, 13, 1418-1431	10.6	89
81	Genetic profiling of and in diffuse large B-cell lymphoma determines cell-of-origin-specific clinical impact. *Blood*, **2017**, 129, 2760-2770	2.2	82
80	The Prognostic Impact of CD163-Positive Macrophages in Follicular Lymphoma: A Study from the BC Cancer Agency and the Lymphoma Study Association. *Clinical Cancer Research*, **2015**, 21, 3428-35	12.9	73
79	Single-Cell Transcriptome Analysis Reveals Disease-Defining T-cell Subsets in the Tumor Microenvironment of Classic Hodgkin Lymphoma. *Cancer Discovery*, **2020**, 10, 406-421	24.4	69
78	Genome-wide discovery of somatic regulatory variants in diffuse large B-cell lymphoma. *Nature Communications*, **2018**, 9, 4001	17.4	64
77	Cell of origin of transformed follicular lymphoma. *Blood*, **2015**, 126, 2118-27	2.2	60
76	Correlations between BCL6 rearrangement and outcome in patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP. *Haematologica*, **2010**, 95, 96-101	6.6	53
75	Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease. *Blood*, **2016**, 127, 2203-13	2.2	51
74	Hypoxia-inducible factor-1 {alpha} expression predicts superior survival in patients with diffuse large B-cell lymphoma treated with R-CHOP. *Journal of Clinical Oncology*, **2010**, 28, 1017-24	2.2	47
73	Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma. *Blood*, **2019**, 134, 761-764	2.2	43
72	Macrophages predict treatment outcome in Hodgkin‘s lymphoma. *Haematologica*, **2011**, 96, 186-9	6.6	42
71	Lymphoma cell VEGFR2 expression detected by immunohistochemistry predicts poor overall survival in diffuse large B cell lymphoma treated with immunochemotherapy (R-CHOP). *British Journal of Haematology*, **2010**, 148, 235-44	4.5	38
70	HLA-DR protein status predicts survival in patients with diffuse large B-cell lymphoma treated on the MACOP-B chemotherapy regimen. *Leukemia and Lymphoma*, **2007**, 48, 542-6	1.9	38

69	High-resolution architecture and partner genes of rearrangements in lymphoma with DLBCL morphology. *Blood Advances*, **2018**, 2, 2755-2765	7.8	38
68	MicroRNA signature obtained from the comparison of aggressive with indolent non-Hodgkin lymphomas: potential prognostic value in mantle-cell lymphoma. *Journal of Clinical Oncology*, **2013**, 31, 2903-11	2.2	36
67	Vascularization predicts overall survival and risk of transformation in follicular lymphoma. *Haematologica*, **2010**, 95, 2157-60	6.6	34
66	Sequential transcription factor targeting for diffuse large B-cell lymphomas. *Cancer Research*, **2008**, 68, 3361-9	10.1	26
65	Identification of high-risk DUSP22-rearranged ALK-negative anaplastic large cell lymphoma. *British Journal of Haematology*, **2019**, 186, e28-e31	4.5	25
64	TBL1XR1 Mutations Drive Extranodal Lymphoma by Inducing a Pro-tumorigenic Memory Fate. *Cell*, **2020**, 182, 297-316.e27	56.2	23
63	Cathepsin S Regulates Antigen Processing and T Cell Activity in Non-Hodgkin Lymphoma. *Cancer Cell*, **2020**, 37, 674-689.e12	24.3	23
62	TMEM30A loss-of-function mutations drive lymphomagenesis and confer therapeutically exploitable vulnerability in B-cell lymphoma. *Nature Medicine*, **2020**, 26, 577-588	50.5	22
61	Outcome of primary mediastinal large B-cell lymphoma using R-CHOP: impact of a PET-adapted approach. *Blood*, **2020**, 136, 2803-2811	2.2	20
60	The pre-B-cell receptor associated protein VpreB3 is a useful diagnostic marker for identifying c-MYC translocated lymphomas. *Haematologica*, **2010**, 95, 2056-62	6.6	20
59	COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study. *Blood Advances*, **2019**, 3, 2013-2021	7.8	19
58	Long-term results of PET-guided radiation in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP. *Blood*, **2021**, 137, 929-938	2.2	19
57	FOXP1 expression is a prognostic biomarker in follicular lymphoma treated with rituximab and chemotherapy. *Blood*, **2018**, 131, 226-235	2.2	19
56	High frequency of MALT lymphoma in a series of 14 cases of primary breast lymphoma. *Applied Immunohistochemistry and Molecular Morphology*, **2002**, 10, 115-20	1.9	16
55	Mutational landscape of gray zone lymphoma. *Blood*, **2021**, 137, 1765-1776	2.2	15
54	Blastic plasmacytoid dendritic cell neoplasm. *Anais Brasileiros De Dermatologia*, **2013**, 88, 158-61	1.6	11
53	. *Applied Immunohistochemistry & Molecular Morphology*, **2002**, 10, 115-120		11
52	Long-Term Follow-up of a PET-Guided Approach to Treatment of Limited-Stage Diffuse Large B-Cell Lymphoma (DLBCL) in British Columbia (BC). *Blood*, **2019**, 134, 401-401	2.2	11

51	Gene expression profiling of gray zone lymphoma. *Blood Advances*, **2020**, 4, 2523-2535	7.8	10
50	Interim PET-directed therapy in limited-stage Hodgkin lymphoma initially treated with ABVD. *Haematologica*, **2018**, 103, e590-e593	6.6	9
49	Characterization of DLBCL with a PMBL gene expression signature. *Blood*, **2021**, 138, 136-148	2.2	9
48	Cell of origin in diffuse large B-cell lymphoma in systemic lupus erythematosus: molecular and clinical factors associated with survival. *Lupus Science and Medicine*, **2019**, 6, e000324	4.6	8
47	Strong p53 Expression Is an Independent Predictor of Outcome in De Novo Diffuse Large B Cell Lymphoma (DLBCL) Treated with Either CHOP or CHOP-R.. *Blood*, **2006**, 108, 812-812	2.2	8
46	Single Cell Phenotypic Profiling of 27 DLBCL Cases Reveals Marked Intertumoral and Intratumoral Heterogeneity. *Cytometry Part A: the Journal of the International Society for Analytical Cytology*, **2020**, 97, 620-629	4.6	8
45	Sustained complete remission of primary effusion lymphoma with adjunctive ganciclovir treatment in an HIV-positive patient. *BMJ Case Reports*, **2014**, 2014,	0.9	7
44	The Impact of Concurrent MYC BCL2 Protein Expression on the Risk of Secondary Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma (DLBCL). *Blood*, **2014**, 124, 495-495	2.2	6
43	Aberrant cytoplasmic expression of MHCII confers worse progression free survival in diffuse large B-cell lymphoma. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2017**, 470, 113-117	5.1	5
42	Transformation of a cutaneous follicle center lymphoma to a diffuse large B-cell lymphoma-an unusual presentation. *Case Reports in Medicine*, **2010**, 2010, 296523	0.7	5
41	The impact of MYC and BCL2 structural variants in tumors of DLBCL morphology and mechanisms of false-negative MYC IHC. *Blood*, **2021**, 137, 2196-2208	2.2	5
40	The Tumor Microenvironment Measured by Flow Cytometry Predicts Overall Survival (OS) and Transformation Risk (TR) in Follicular Lymphoma.. *Blood*, **2006**, 108, 2406-2406	2.2	4
39	Clinical Significance of Genetic Aberrations in Diffuse Large B Cell Lymphoma. *Blood*, **2014**, 124, 703-703	2.2	4
38	Mechanisms of Bcl-2 Protein Expression in Diffuse Large B-Cell Lymphoma (DLBCL).. *Blood*, **2004**, 104, 26-26	2.2	3
37	Addition of Rituximab (R) to CHOP Improves Survival in the Non-GCB Subtype of Diffuse Large B Cell Lymphoma (DLBCL).. *Blood*, **2006**, 108, 816-816	2.2	3
36	The Architecural Pattern of FOXP3+ T Cells Predicts Risk of Transformation in Patients with Follicular Lymphoma (FL).. *Blood*, **2007**, 110, 358-358	2.2	3
35	Predicting survival in follicular lymphoma using tissue microarrays. *Methods in Molecular Biology*, **2007**, 377, 255-68	1.4	3
34	Hepatosplenic T-cell lymphoma: a rare cause of hepatosplenomegaly. *BMJ Case Reports*, **2014**, 2014,	0.9	2

33	Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 As a Therapeutic Target for Restoring MHC Expression in Diffuse Large B-Cell Lymphoma. *Blood*, **2018**, 132, 1560-1560	2.2	2
32	Expression of Hypoxia-Inducible Factor (HIF) Is An Independent Favorable Prognostic Factor in Diffuse Large B-Cell Lymphoma (DLBCL) Treated with R-CHOP. *Blood*, **2008**, 112, 479-479	2.2	2
31	HLA-DR Protein Expression Correlates with Non-Neoplastic T-Cell Infiltration and Predicts Survival in Patients with Primary Mediastinal Large B Cell Lymphoma (PMBCL) Treated with CHOP Chemotherapy.. *Blood*, **2009**, 114, 133-133	2.2	2
30	Single-cell profiling reveals the importance of CXCL13/CXCR5 axis biology in lymphocyte-rich classic Hodgkin lymphoma. *Proceedings of the National Academy of Sciences of the United States of America*, **2021**, 118,	11.5	2
29	Combined FOXP3+ and PD1+ T Cell Density and Architectural Patterns Predict Overall Survival and Risk of Transformation in Uniformly Treated Patients with Follicular Lymphoma. *Blood*, **2008**, 112, 2815-2815	2.2	2
28	The Double-Hit Gene Expression Signature Defines a Clinically and Biologically Distinct Subgroup within GCB-DLBCL. *Blood*, **2018**, 132, 921-921	2.2	1
27	Single Cell Transcriptome Analysis Reveals Disease-Defining T Cell Subsets in the Tumor Microenvironment of Classic Hodgkin Lymphoma. *Blood*, **2019**, 134, 547-547	2.2	1
26	TP53 Expression Correlates with TP53 Mutations and Is an Independent Predictor of Clinical Outcome in Patients with DLBCL Treated with R-CHOP. *Blood*, **2019**, 134, 3964-3964	2.2	1
25	The Percentage of Cytotoxic T-Cells in Mantle Cell Lymphoma (MCL) Biopsies Predicts Response to Rituximab.. *Blood*, **2009**, 114, 2923-2923	2.2	1
24	Number of Lymphoma-Associated-Macrophages (LAM) Is An Independent Predictor of Survival in Patients with Mantle Cell Lymphoma (MCL).. *Blood*, **2009**, 114, 3944-3944	2.2	1
23	Cell-of-Origin Assignment in Diffuse Large B-Cell Lymphoma Determined By Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Has Prognostic Significance Independent of IPI and MYC/BCL2 Immunohistochemistry. *Blood*, **2014**, 124, 1624-1624	2.2	1
22	Comprehensive MYC and BCL2 Genetic Profiling in De Novo Diffuse Large B-Cell Lymphoma Demonstrates Clinically Relevant Genetic Alterations According to Cell of Origin Subtype. *Blood*, **2015**, 126, 109-109	2.2	1
21	The impact of surveillance imaging after curative-intent radiotherapy for limited-stage follicular lymphoma. *British Journal of Haematology*, **2021**, 195, 802-805	4.5	1
20	Genome-wide discovery of somatic coding and regulatory variants in Diffuse Large B-cell Lymphoma		1
19	Gene Expression Profiling of Microdissected Hodgkin Reed Sternberg Cells: Molecular Subtypes and Treatment Outcome Correlations.. *Blood*, **2009**, 114, 268-268	2.2	1
18	BCL2 Expression in First-Line Diffuse Large B-Cell Lymphoma Identifies a Patient Population With Poor Prognosis. *Clinical Lymphoma, Myeloma and Leukemia*, **2021**, 21, 267-278.e10	2	1
17	Prognostic significance of FCGR2B expression for the response of DLBCL patients to rituximab or obinutuzumab treatment. *Blood Advances*, **2021**, 5, 2945-2957	7.8	1
16	Mutations in the transcription factor FOXO1 mimic positive selection signals to promote germinal center B cell expansion and lymphomagenesis. *Immunity*, **2021**, 54, 1807-1824.e14	32.3	1

List of Publications

15	Lymphoma-Associated Macrophage (LAM) Content Is an Independent Predictor of Survival in Patients with Follicular Lymphoma (FL).. *Blood*, **2004**, 104, 3259-3259	2.2	0
14	Diffuse Large B-Cell Lymphoma (DLBCL) Patients with Late Relapses Who Are Transplant-Eligible Have Excellent Outcomes and May Represent Unique Biology. *Blood*, **2021**, 138, 2499-2499	2.2	0
13	Outcome of limited-stage nodular lymphocyte-predominant Hodgkin lymphoma and the impact of a PET-adapted approach. *Blood Advances*, **2021**, 5, 3647-3655	7.8	0
12	Primary cutaneous follicle center lymphoma of the medial canthus of the eye in an 11-year old.. *Pediatric Blood and Cancer*, **2022**, e29630	3	0
11	Fever and generalised lymphadenopathy in an HIV-positive patient: a diagnostic challenge. *BMJ Case Reports*, **2017**, 2017,	0.9	
10	Single Cell Profiling Reveals Unique CXCL13 Positive T Cell Subsets in the Tumor Microenvironment of Lymphocyte Rich Classic Hodgkin Lymphoma. *Blood*, **2020**, 136, 32-33	2.2	
9	Constrained FL: A Genetically Distinct Subgroup of Follicular Lymphoma with Low Rates of Somatic Hypermutation and a Reduced Propensity for Histologic Transformation. *Blood*, **2021**, 138, 807-807	2.2	
8	Immune Profiling of Diagnostic DLBCL Biopsies Dramatically Improves upon Cell-of-Origin Risk Stratification. *Blood*, **2021**, 138, 719-719	2.2	
7	HLA-DR Protein Status Predicts Survival in Patients with Diffuse Large B Cell Lymphoma (DLBCL) Treated with the MACOP-B Chemotherapy Regimen.. *Blood*, **2004**, 104, 3273-3273	2.2	
6	Vascularization Predicts Overall Survival (OS) & Risk of Transformation (RT) in Uniformly Treated Patients with Follicular Lymphoma (FL).. *Blood*, **2007**, 110, 184-184	2.2	
5	PRAME Expression Is Correlated with Treatment Outcome and Specific Features of the Tumor Microenvironment in Classical Hodgkin Lymphoma. *Blood*, **2019**, 134, 1509-1509	2.2	
4	Intravascular large B-cell lymphoma presenting with acute encephalopathy. *Blood*, **2020**, 135, 1916	2.2	
3	Genetic Alterations of G13 Signaling Pathway with BCL2 over-Expression Confers Lymphoma Dissemination and Inferior Outcome in Germinal Center B Cell Diffuse Large B Cell Lymphoma. *Blood*, **2015**, 126, 111-111	2.2	
2	Targeted Sequencing Reveals Novel Gene Mutations Associated with Transformation and Early Progression in Follicular Lymphoma. *Blood*, **2016**, 128, 2919-2919	2.2	
1	Divergent Modes of Tumor Evolution Underlie Histological Transformation and Early Progression of Follicular Lymphoma. *Blood*, **2016**, 128, 1091-1091	2.2	